Table 1.
Age at time of the liver biopsy of 60 patients with neonatal and infantile liver disease
| Disease | Number of cases | Age at time of liver biopsy (days) (Mean +/− S.D.) |
|---|---|---|
| PIBD | 16 | 137.87 +/− 147.93 (S.E.M.: 38.19 days) |
| BA | 10 | 87.00 +/− 61.49 (S.E.M.: 20.5 days) |
| NH | 9 | 109.38 +/− 93.08 (S.E.M.: 32.91 days) |
| NC-NOS | 5 | 70.60 +− 67.11 (S.E.M.: 30.01 days) |
| Gly-I | 3 | 295 +/− 191.23 (S.E.M.: 110.41 days) |
| CHF | 2 | 227.5 +/− 74.25 |
| CVD-HI | 2 | 294.5 +/− 70.00 |
| DILD | 2 | 292.0 +/− 42.43 |
| FFAOD | 2 | 70.00 +/− 42.46 |
| CC-LD | 1 | 174 |
| APO-LD | 1 | 266 |
| PDHP-LD | 1 | 343 |
| CMV-H | 1 | 88 |
| WFASS | 1 | 418 |
| CID-NOS | 1 | 106 |
| NBLD-NOS | 1 | 144 |
| NEC-LD | 1 | 140 |
| Sepsis | 1 | 12 |
APO-LD (annular pancreas obstruction-associated liver disease), BA (biliary atresia), CC-LD (choledocal cyst-associated liver disease), CID NOS (congenital immunodeficiency, not otherwise specified), CHF (congenital hepatic fibrosis), CMV-H (cytomegalovirus hepatitis), CVD-HI (cardiovascular disease with hepatic involvement), DILD (drug-induced liver disease), FFAOD (fetal fatty acid oxidation disorder associated with maternal HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), GlyI (glycogenosis type I), NC NOS (neonatal cholestasis not otherwise specified), NH (neonatal hepatitis), PDHP-LD (liver disease associated with deficiency of pyruvate dehydrogenase phosphate), PIBD (paucity of intrahepatic bile ducts), NBLD NOS (nonbiliary liver disease not otherwise specified), NEC-LD (hepatic involvement associated with necrotizing enterocolitis), and WFASS (Wissler-Fanconi allergic subsepsis syndrome). S.D.: standard deviation, S.E.M.: standard error of the mean.